As previously reported on, common equine internal parasites such as roundworms and strong strongyles are developing resistance against most of the commercially available deworming products. To compound the problem, no new deworming products are likely to become available in the near future.

With no knight in shining armor coming to the rescue, the equine industry must seek alternate strategies to manage internal parasites in horses, such as re-evaluating existing dewormers.

Now, a Turkish research group from the Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine at Adnan Menderes University has done just this.

Netobimin is a pro-drug form of albendazole, which is in the same drug class as fenbendazole. Netobimin is currently used in ruminants, but has not yet been evaluated in horses.

In the study, “Pharmacological assessment of netobimin as a potential anthelmintic for use in horses: Plasma disposition, faecal excretion and efficacy,” the researchers found that netobimin was metabolized to various compounds, including albendazole, and effectively reduced fecal strongyle egg counts by 100%, 100%, 77%, 80%, and 75% at weeks 2, 4, 6, 8, and 10 post-treatment, respectively.

Based on these positive results, the authors suggest that, “netobimin could be effective as an anthelminitic in horses.” More research to establish safety and tolerance of netobimin are needed.

This study is scheduled to be published in the journal Research in Veterinary Science. The abstract is currently available on PubMed.